Ann: Appendix 4C - quarterly, page-55

All good. I agree that the trial, in its current form, obviously does not seem compelling enough for patients to enroll into.

But to look on the bright side, management know this, and one would think that the only way left to go is up. We would be foolish to believe that the trial won't be improved and more incentives are provided to patients to enrol.

We have a solid cash stockpile and $4m more in cash expected from conversion of the IBXOs by November.

There will undoubtedly be more delays (unavoidable with biotech specs), but the trial will happen eventually. Tickets to get on board are on special atm